Hyun Ah Kim1, Yunshin Yeo, Wan-Uk Kim, Suho Kim. 1. Division of Rheumatology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Dongan-Gu, Anyang, Korea. kimha@hallym.ac.kr
Abstract
OBJECTIVES: In addition to its chemopreventive activity, phase 2 enzyme inducers have been recently found to have anti-inflammatory activity. In this study, we examined the influence of sulphoraphane (SPN), one of the most potent inducers of the phase II enzymes on the production of MMPs by pro-inflammatory cytokines in human articular chondrocytes. METHODS: Articular cartilages were obtained from knee OA patients and were cultured in monolayers and explants. Induction of a phase II enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO1), in chondrocytes was assayed after incubation with various concentrations of SPN. Chondrocytes were stimulated with IL-1 or TNF-alpha with or without pre-incubation with SPN. The expression and activation of MMP-1, -3 and -13 was evaluated by an ELISA, gel zymography and RT-PCR. MAP kinases [p38, extracellular signal-regulated protein kinase (ERK) and C-Jun N terminal kinase (JNK)] and NF-kappaB activation were evaluated by western blotting and by an electrophoretic mobility shift assay, respectively. RESULTS: SPN significantly induced NQO1 activity in chondrocytes and the induction was maximal at 24 h. SPN inhibited the production of MMP-1, -3 and -13 protein and mRNA induced by either IL-1 or TNF-alpha in a dose-dependent manner. This inhibition of MMP by SPN was accompanied by the inhibition of NF-kappaB and JNK activation. CONCLUSIONS: SPN was found to inhibit MMP production in pro-inflammatory cytokine-stimulated chondrocytes. Delineation of the biochemical mechanism regulating cartilage catabolism by SPN may identify safe and effective therapeutic targets for the inhibition of cartilage degradation.
OBJECTIVES: In addition to its chemopreventive activity, phase 2 enzyme inducers have been recently found to have anti-inflammatory activity. In this study, we examined the influence of sulphoraphane (SPN), one of the most potent inducers of the phase II enzymes on the production of MMPs by pro-inflammatory cytokines in human articular chondrocytes. METHODS: Articular cartilages were obtained from knee OA patients and were cultured in monolayers and explants. Induction of a phase II enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO1), in chondrocytes was assayed after incubation with various concentrations of SPN. Chondrocytes were stimulated with IL-1 or TNF-alpha with or without pre-incubation with SPN. The expression and activation of MMP-1, -3 and -13 was evaluated by an ELISA, gel zymography and RT-PCR. MAP kinases [p38, extracellular signal-regulated protein kinase (ERK) and C-Jun N terminal kinase (JNK)] and NF-kappaB activation were evaluated by western blotting and by an electrophoretic mobility shift assay, respectively. RESULTS:SPN significantly induced NQO1 activity in chondrocytes and the induction was maximal at 24 h. SPN inhibited the production of MMP-1, -3 and -13 protein and mRNA induced by either IL-1 or TNF-alpha in a dose-dependent manner. This inhibition of MMP by SPN was accompanied by the inhibition of NF-kappaB and JNK activation. CONCLUSIONS:SPN was found to inhibit MMP production in pro-inflammatory cytokine-stimulated chondrocytes. Delineation of the biochemical mechanism regulating cartilage catabolism by SPN may identify safe and effective therapeutic targets for the inhibition of cartilage degradation.
Authors: Rose Davidson; Sarah Gardner; Orla Jupp; Angela Bullough; Sue Butters; Laura Watts; Simon Donell; Maria Traka; Shikha Saha; Richard Mithen; Mandy Peffers; Peter Clegg; Yongping Bao; Aedin Cassidy; Ian Clark Journal: Sci Rep Date: 2017-06-13 Impact factor: 4.379
Authors: Pablo Ferreira-Chamorro; Alejandro Redondo; Gabriela Riego; Sergi Leánez; Olga Pol Journal: Front Pharmacol Date: 2018-11-20 Impact factor: 5.810
Authors: Rose K Davidson; Orla Jupp; Rachel de Ferrars; Colin D Kay; Kirsty L Culley; Rosemary Norton; Clare Driscoll; Tonia L Vincent; Simon T Donell; Yongping Bao; Ian M Clark Journal: Arthritis Rheum Date: 2013-12